Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Common Equity (2016 - 2025)

Immucell (ICCC) has disclosed Common Equity for 16 consecutive years, with $29.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Common Equity rose 12.83% year-over-year to $29.8 million, compared with a TTM value of $29.8 million through Sep 2025, up 12.83%, and an annual FY2024 reading of $27.5 million, up 10.1% over the prior year.
  • Common Equity was $29.8 million for Q3 2025 at Immucell, roughly flat from $29.9 million in the prior quarter.
  • Across five years, Common Equity topped out at $33.2 million in Q1 2022 and bottomed at $23.5 million in Q2 2024.
  • Average Common Equity over 5 years is $28.9 million, with a median of $29.0 million recorded in 2025.
  • The sharpest move saw Common Equity fell 18.66% in 2023, then rose 27.34% in 2025.
  • Year by year, Common Equity stood at $32.6 million in 2021, then fell by 6.74% to $30.4 million in 2022, then decreased by 17.73% to $25.0 million in 2023, then grew by 10.1% to $27.5 million in 2024, then grew by 8.3% to $29.8 million in 2025.
  • Business Quant data shows Common Equity for ICCC at $29.8 million in Q3 2025, $29.9 million in Q2 2025, and $29.0 million in Q1 2025.